Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Privia Health (PRVA) Cash & Equivalents (2020 - 2026)

Privia Health has reported Cash & Equivalents over the past 6 years, most recently at $479.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.33% year-over-year to $479.7 million; the TTM value through Dec 2025 reached $479.7 million, down 2.33%, while the annual FY2025 figure was $479.7 million, 2.33% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $479.7 million at Privia Health, up from $441.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $491.1 million in Q4 2024 and troughed at $81.9 million in Q1 2021.
  • A 5-year average of $355.9 million and a median of $349.6 million in 2022 define the central range for Cash & Equivalents.
  • On a YoY basis, Cash & Equivalents climbed as much as 285.57% in 2022 and fell as far as 12.49% in 2022.
  • Year by year, Cash & Equivalents stood at $320.6 million in 2021, then increased by 8.55% to $348.0 million in 2022, then rose by 11.93% to $389.5 million in 2023, then rose by 26.09% to $491.1 million in 2024, then decreased by 2.33% to $479.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for PRVA at $479.7 million in Q4 2025, $441.4 million in Q3 2025, and $390.1 million in Q2 2025.